Arvelle Therapeutics Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 60

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $960M

  • Investors
  • 1

Arvelle Therapeutics General Information

Description

Operator of a biopharmaceutical company intended to deliver innovative treatments to patients suffering from CNS disorders. The company's therapies serve patients suffering from central nervous system disorders for debilitating neurological and neuromuscular diseases and are responsible for the development and commercialization of Cenobamate, enabling clinicians to provide proper medical care for focal seizures of patients.

Contact Information

Website
www.arvelletx.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • Zählerweg 6
  • 6301 Zug
  • Switzerland
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Acquirer
Angelini Pharma
Vertical(s)
Life Sciences
Corporate Office
  • Zählerweg 6
  • 6301 Zug
  • Switzerland

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Arvelle Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 02-Feb-2021 $960M Completed Generating Revenue
2. Early Stage VC (Series A) 26-May-2020 Completed Generating Revenue
1. Corporate 01-Feb-2019 Completed Startup
To view Arvelle Therapeutics’s complete valuation and funding history, request access »

Arvelle Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biopharmaceutical company intended to deliver innovative treatments to patients suffering from CNS disorde
Drug Discovery
Zug, Switzerland
60 As of 2021

Cambridge, MA
 

Kalamazoo, MI
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Arvelle Therapeutics Competitors (32)

One of Arvelle Therapeutics’s 32 competitors is SAGE Therapeutics, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
SAGE Therapeutics Formerly VC-backed Cambridge, MA
Metabolic Solutions Development Company Venture Capital-Backed Kalamazoo, MI
Xenon Pharmaceuticals Formerly VC-backed Burnaby, Canada
NeuroDerm Formerly VC-backed Rehovot, Israel
Centrose Venture Capital-Backed Middleton, WI
You’re viewing 5 of 32 competitors. Get the full list »

Arvelle Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Arvelle Therapeutics Former Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Andera Partners PE/Buyout Minority
BRV Capital Management Growth/Expansion Minority
EQT Life Sciences Venture Capital Minority
Eight Roads Corporate Venture Capital Minority
F-Prime Capital Venture Capital Minority
You’re viewing 5 of 9 investors. Get the full list »

Arvelle Therapeutics Investments (1)

Arvelle Therapeutics’s most recent deal was a Corporate Asset Purchase with Cenobamate Drug Development and Commercial rights for Europe for . The deal was made on 20-Feb-2019.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Cenobamate Drug Development and Commercial rights for Europe 20-Feb-2019 Corporate Asset Purchase Buildings and Property
To view Arvelle Therapeutics’s complete investments history, request access »

Ready to get started?

Request a free trial

Arvelle Therapeutics FAQs

  • When was Arvelle Therapeutics founded?

    Arvelle Therapeutics was founded in 2019.

  • Where is Arvelle Therapeutics headquartered?

    Arvelle Therapeutics is headquartered in Zug, Switzerland.

  • What is the size of Arvelle Therapeutics?

    Arvelle Therapeutics has 60 total employees.

  • What industry is Arvelle Therapeutics in?

    Arvelle Therapeutics’s primary industry is Drug Discovery.

  • Is Arvelle Therapeutics a private or public company?

    Arvelle Therapeutics is a Private company.

  • What is the current valuation of Arvelle Therapeutics?

    The current valuation of Arvelle Therapeutics is .

  • What is Arvelle Therapeutics’s current revenue?

    The current revenue for Arvelle Therapeutics is .

  • How much funding has Arvelle Therapeutics raised over time?

    Arvelle Therapeutics has raised $223M.

  • Who are Arvelle Therapeutics’s investors?

    Andera Partners, BRV Capital Management, EQT Life Sciences, Eight Roads, and F-Prime Capital are 5 of 9 investors who have invested in Arvelle Therapeutics.

  • Who are Arvelle Therapeutics’s competitors?

    SAGE Therapeutics, Metabolic Solutions Development Company, Xenon Pharmaceuticals, NeuroDerm, and Centrose are some of the 32 competitors of Arvelle Therapeutics.

  • When was Arvelle Therapeutics acquired?

    Arvelle Therapeutics was acquired on 02-Feb-2021.

  • Who acquired Arvelle Therapeutics?

    Arvelle Therapeutics was acquired by Angelini Pharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »